-
bluebird bio (BLUE) PT Lowered to $31 at BMO Capital
-
bluebird bio (BLUE) PT Lowered to $36 at BMO Capital
-
UPDATE: BMO Capital Downgrades bluebird bio (BLUE) to Market Perform
-
bluebird bio (BLUE) PT Lowered to $159 at BMO Capital
-
bluebird bio (BLUE) PT Lowered to $163 at BMO Capital
-
bluebird bio (BLUE) PT Lowered to $191 at BMO Capital
-
bluebird bio (BLUE) PT Lowered to $216 at BMO Capital; ASCO Next Major Catalyst
-
bluebird bio (BLUE) PT Raised to $222 at BMO Capital
-
bluebird bio (BLUE) PT Raised to $215 at BMO Capital Following ASH Conference
-
bluebird bio (BLUE): Buy If ASH Data Causes Weakness - BMO
-
bluebird bio (BLUE) PT Raised to $134 at BMO Capital
-
BMO Capital Upgrades bluebird bio (BLUE) to Outperform
-
BMO Capital Reiterates Market Perform Rating and $83 PT on Bluebird Bio (BLUE)
-
bluebird bio (BLUE) PT Raised to $83 at BMO as bb2121 Shows Promising Efficacy, Clean Safety
-
BMO Capital Starts bluebird bio (BLUE) at Market Perform
-
Pre-Open Stock Movers 06/22: (WMB) (CNIT) (FIT) (CI) Higher; (MSO) (ZIOP) (WPZ) Lower (more...)
-
bluebird bio (BLUE) PT Lifted to $239 at BMO Capital Following Impressive LentiGlobin Update
-
BMO Capital Sees 'Deminimus Impact' on bluebird bio (BLUE) Valuation Even If Launch Delayed
-
bluebird bio (BLUE) Demonstrates Strong Proof-of-Concept for LentiGlobin in SCD, BMO Capital Notes
-
bluebird bio (BLUE) PT Raised to $200 at BMO Capital Ahead of SCD Data for LentiGlobin at EHA
-
Buy Broader Gene Therapy Group on Weakness Related to Celadon (CLDN) Failure, BMO Says (AGTC) (BLUE) (SGMO) (QURE)
-
Notable Analyst Rating Changes 4/23: (POT) (SYF) (RGR) Upgraded; (RIG) (QCOM) (ANGI) Downgraded
-
UPDATE: BMO Capital Starts Bluebird Bio (BLUE) at Outperform
-
Notable 52-Week Highs and 12/10: (UAL) (BLUE) (BMS) High; (OAS) (CVEO) (CONN) Low
-
Notable Analyst Rating Changes 07/15: (LEAP) (DECK) (TIF) Upgraded; (VVUS) (UPS) (QLGC) Downgraded